Summit Therapeutics Inc.
SMMT
Rang in aandelen
#1699
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Aandeelprijs
$15.80
Marktkapitalisatie
$12.61B
Verandering (1 dag)
-1.78%
Verandering (1 jaar)
-15.67%
Land
US
Handel Summit Therapeutics Inc. (SMMT)
Categorie
Healthcare
Omzet van Summit Therapeutics Inc. (SMMT)
Omzet in Jun 2026 TTM: 0.00
Volgens de laatste financiële rapporten van Summit Therapeutics Inc. bedraagt de huidige omzet van het bedrijf (TTM) 0.00. In 2023 behaalde het bedrijf een omzet van 0.00 een daling ten opzichte van de omzet in het jaar 2022, die $704.30K bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Summit Therapeutics Inc. van 2004 tot 2026
Omzet aan het einde van elk jaar
| Jaar | Omzet | Wijzigen |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | $704.30K | -61.07% |
| 2021 | $1.81M | 110.35% |
| 2020 | $860.00K | 5.99% |
| 2019 | $811.40K | -96.73% |
| 2018 | $24.84M | 585.22% |
| 2017 | $3.63M | 98.76% |
| 2016 | $1.82M | -46.59% |
| 2015 | $3.42M | -8.39% |
| 2014 | $3.73M | -17.91% |
| 2013 | $4.54M | 3.93% |
| 2012 | $4.37M | 126.58% |
| 2011 | $1.93M | 297.91% |
| 2010 | $484.72K | 26.56% |
| 2009 | $383.00K | -96.80% |
| 2008 | $11.98M | 201.54% |
| 2007 | $3.97M | 135.85% |
| 2006 | $1.68M | 320.18% |
| 2005 | $400.93K | 11,995.06% |
| 2004 | $3.31K | 0.00% |
Omzet van vergelijkbare bedrijven of concurrenten
| Bedrijf | Omzet | Omzetverschil | Land |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
